Stents are usually used in the treatment of coronary angioplasty or percutaneous coronary intervention producers. The types of drug eluting stents include bare metal coronary artery stents, coronary artery restenosis, coronary artery stents, coronary revascularization, and others. Coronary artery stents are small cylindrical device that helps in improving blood flow through arteries to the heart by reducing blockages in the artery. Coronary artery stents are more beneficial for patients suffering from coronary artery diseases such as myocardial infarction.
Market Dynamics
Different Manufacturers like Boston Scientific., Medtronic, and others are focused on developing and launching new products and receiving product approvals from the United States Food and Drug Administration (U.S.FDA). For instance, in April 2019, Shanghai-based medical company MicroPort Medical (Group) Co., Ltd. received the U.S.FDA approval and CE (Conformité Européenne) Mark for ‘Firehawk Liberty’, a new generation rapamycin target eluting coronary stent system.
Furthermore, in May 2022, key players such as Medtronic, a global medical technology company, obtained the U.S. Food and Drug Administration (FDA) approval for Onyx Frontier drug-elution stent (DES), used to treat blockage of the heart arteries. It has enhanced delivering system and increased acute performance which is used to treat patients suffering from coronary artery disease. Onyx Frontier provides 4.50-5.00 mm sizes that can be expanded to 6.00 mm. It is specifically, designed to support extra-large vessels, while it shares the clinical indications as Resolute Onyx, including the most recent approval for patients that are at high risk of bleeding and may benefit from a dual anti-platelet therapy (DAPT) duration.
Moreover, an increase in the awareness of cardiovascular diseases such as heart failure and coronary heart disease cases globally is expected to fuel the global drug eluting stents market growth over the forecast period. For instance, in January 2020, according to the data published by the American Heart Association (AHA), the awareness of coronary artery disease is higher in females (54.4%) than males (45.6%). The mortality rate is also higher in females than in males with myocardial infarction (a dangerous condition caused by a lack of blood flow to the heart muscle).
Key features of the study:
- This report provides an in-depth analysis of the global drug eluting stents market, market size (US$ Mn), and the compound annual growth rate (CAGR) (%) for the forecast period (2022-2030), considering 2021 as a base year
- It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, new product launches or approval, pipeline products, regional outlook, and competitive strategy adopted by the leading players.
- It profiles leading players in the global drug eluting stents market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future product launches, market expansion, and marketing tactics
- Key companies covered as a part of this study include Boston Scientific Corporation, Medtronic, Abbott Laboratories, Biosensors International Group, Biotronik, Lepu Medical Technology, Terumo Medical Corporation, Cook Medical, Shandong JW Medical Systems, Stentys, AlviMedica Medical Technologies Inc., Amaranth Medical, Inc., HangZhou HuaAn Biotechnology Co., Ltd, XTENT, Inc., Cardionovum GmbH, Cordis Corporation, and Kyoto Medical Planning Co., Ltd.
- The global drug eluting stents market report caters to various stakeholders in this industry, including investors, product developers, distributors, healthcare companies, research institutes, medical device companies, new entrants, and financial analysts
- The global drug eluting stents market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would greatly benefit in decision-making through the various strategy matrices used in analyzing the global drug eluting stents market
Detailed Segmentation:
- Global Drug Eluting Stents Market, By Drug
- Sirolimus
- Paclitaxel
- Zotarolimus
- Everolimus
- Biolimus
- Others
- Global Drug Eluting Stents Market, By Coating Type
- Polymer-based Coatings
- Polymer-free Coatings
- Global Drug Eluting Stents Market, By Application:
- Coronary Artery Diseases
- Peripheral Artery Diseases
- Global Drug Eluting Stents Market, By End User:
- Cardiology Centers
- Ambulatory Surgery Centers (ASCs)
- Hospitals
- Global Drug Eluting Stents Market, By Region
- North America
- Europe
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- Boston Scientific Corporation
- Company Overview
- Product Portfolio
- Market Presence
- Financial Overview
- Key Developments
- Strategies
- Medtronic, Plc.
- Abbott Laboratories
- Biosensors International Group
- Biotronik
- Lepu Medical Technology
- Terumo Medical Corporation
- Cook Medical
- Shandong JW Medical Systems
- Stentys
- AlviMedica Medical Technologies Inc.
- Amaranth Medical, Inc.
- HangZhou HuaAn Biotechnology Co.,Ltd
- XTENT, Inc.
- Cardionovum GmbH
- Cordis Corporation
- Kyoto Medical Planning Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
